ClearPoint Neuro, Inc. (CLPT) (the “Company”) today provided an update with respect to the COVID-19 pandemic and announced preliminary financial results for the quarter ended March 31, 2020. “Given the unprecedented events resulting from the COVID-19 pandemic, we are providing this update to patients, our hospital customers, our employees and our investors, to inform how the pandemic is affecting our business, and to comment on what we believe continues to be the strength and resiliency of our Company,” commented Joe Burnett, ClearPoint Neuro’s President and CEO.

MRI Interventions, Inc. (MRIC) (the “Company”), a leading platform neurosurgery company, today announced preliminary and unaudited results for the quarter ended December 31, 2019. Additionally, the Company announced a $17.5 million strategic investment from PTC Therapeutics, Inc. (“PTC”) and Petrichor Healthcare Capital Management (“Petrichor”). Revenue for the quarter ended December 31, 2019 is expected to be approximately $3.2 million, a new quarterly revenue record and an increase of 43% from $2.3 million in the prior year fourth quarter.

ClearPoint Neuro, Inc. (CLPT) (the “Company”) today announced that it will release financial results for its 2020 first quarter, which ended March 31, 2020, on Tuesday, May 12, 2020 after the market close. The Company will subsequently conduct a conference call and webcast that day to review its results at 4:30 p.m. Eastern (1:30 p.m. Pacific). A live and archived webcast may be accessed by visiting the company's website at www.clearpointneuro.com, by selecting “Investors” / “News” / “IR Calendar.”

ClearPoint Neuro, Inc. (CLPT) is pleased to announce that Matthew B. Klein, MD, MS, FACS, has been appointed to ClearPoint Neuro’s Board of Directors effective immediately. Dr. Klein, Chief Development Officer of PTC Therapeutics, Inc. (“PTC”), is a veteran biotechnology company executive with extensive experience in drug discovery and development, and a board-certified surgeon. Mr. Souza, who resigned from his position as PTC’s Chief Operating Officer, as was announced by PTC on March 16, 2020, will remain on ClearPoint Neuro’s Board as an independent member.

IRVINE, Calif., Sept. 12, 2019 -- MRI Interventions, Inc. (NYSE American: MRIC) today announced that Chief Executive Officer Joe Burnett will present at the at the Sidoti Fall.

MRI Interventions, Inc. (NYSE American: MRIC) (the “Company”) today announced that it will voluntarily move its stock exchange listing from the NYSE American LLC to the Nasdaq Capital Market. As a neuro platform company that bridges medical devices with biologics and gene therapy, we feel that Nasdaq is a natural fit and already includes many of our existing and prospective partners in this space.

MRI Interventions, Inc. (MRIC) (the “Company”), a leading platform neurosurgery company, closed its previously announced $17.5 million strategic investment from PTC Therapeutics, Inc. (“PTC”) and Petrichor Healthcare Capital Management (“Petrichor”), with $10.0 million of notes funded by PTC and $7.5 million of notes funded by Petrichor. Under the terms of the investment, the Company also has the right to issue up to $15.0 million of additional secured convertible notes to Petrichor at any time on or prior to January 11, 2022.

NEW YORK, NY / ACCESSWIRE / February 12, 2020 / MRI Interventions, Inc. (NASDAQ:MRIC) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 12, 2020 ...

IRVINE, Calif., Nov. 12, 2019 -- MRI Interventions, Inc. (NYSE American: MRIC) (the “Company”) today announced financial results for its third fiscal quarter ended September.

“This milestone is a testament to the value surgeons are placing on precision guided therapy, especially in neurosurgery where the stakes are the highest,” commented Joe Burnett, President and CEO of MRI Interventions. It is also important to note that not only did UCSF perform the 3,000th case using ClearPoint, they also performed the 3,001st case that same day. MRI Interventions is a leading platform company for MRI-guided neurosurgery procedures, including deep-brain stimulation, ablation, aspiration, biopsy, and gene therapy delivery.

MRI Interventions, Inc. (MRIC) (the “Company”), a leading platform neurosurgery company, today announced plans to change its corporate name to ClearPoint Neuro, Inc. As part of the name change, the Company will release a new logo and launch a new website at www.clearpointneuro.com, and its common stock will commence trading under the symbol “CLPT” upon completion of the name change, which is expected to occur on February 14, 2020. The new name was chosen to better reflect the Company’s expanded strategic focus as the medical device extension of its biologics and drug delivery partners. The name ClearPoint reflects our success in those efforts and leverages our proven ClearPoint® System already present in more than 60 active clinical sites in the United States.

It might be of some concern to shareholders to see the MRI Interventions, Inc. (NYSEMKT:MRIC) share price down 18% in...

MRI Interventions, Inc. (NYSE American: MRIC), a platform neurosurgery company with products designed to deliver navigation, ablation, deep brain stimulation, biopsy and gene therapy, today announced that it will release financial results for its 2019 third quarter, which ended September 30, 2019, on Tuesday, November 12, 2019 after the market close. Statements regarding the company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws.

MRI Interventions, Inc. (NYSE American: MRIC) is pleased to announce that B. Kristine Johnson has been appointed to MRI Interventions’ Board of Directors, effective September 1, 2019. Ms. Johnson, President of Affinity Capital Management, a venture firm that invests primarily in healthcare companies, brings more than 35 years of healthcare management leadership. "We are thrilled to have Kris join our Board, and we can't wait to have the benefit of her expertise as we continue to build our company into the next substantive and diversified player in the neuro medical device space," commented Joe Burnett, President and CEO at MRI Interventions.

IRVINE, Calif., Feb. 12, 2020 -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (formerly, MRI Interventions, Inc.; the “Company”) today announced financial results for its fourth.

ClearPoint Neuro, Inc. (Nasdaq:CLPT) (formerly, MRI Interventions, Inc.; the “Company”, formerly Nasdaq: MRIC) today announced that it will release financial results for its 2019 fourth quarter and full year, which ended December 31, 2019, on Wednesday, February 12, 2020 after the market close. Investors and analysts are invited to listen to a live broadcast review of the Company's 2019 fourth quarter and full year financial results today at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) that may be accessed by visiting the Company's website at www.clearpointneuro.com and selecting “Investors” / “News” / “IR Calendar.” Investors and analysts who would like to participate in the conference call may do so via telephone at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada.

MRI Interventions, Inc. (MRIC) (the “Company”), a leading platform neurosurgery company, will effectuate its previously announced change of its corporate name to ClearPoint Neuro, Inc. tomorrow, February 12, 2020. As part of the name change, the Company will release a new logo and launch a new website at www.clearpointneuro.com. As previously announced, ClearPoint Neuro is scheduled to ring the Closing Bell of the Nasdaq Stock Market on February 14, 2020.

ClearPoint Neuro, Inc. (CLPT) (the “Company”), a leading platform neurosurgery company, today announced a strategic agreement with PTC Therapeutics, Inc. (“PTC”). The scope of the agreement includes hardware, software, clinical case and market development services for gene therapy cases in the United States and Europe to support PTC’s potential commercialization in gene therapy globally upon regulatory approval.

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

ClearPoint Neuro, Inc. (CLPT) (the “Company”) today announced that it will release financial results for its 2020 first quarter, which ended March 31, 2020, on Tuesday, May 12, 2020 after the market close. A live and archived webcast may be accessed by visiting the company's website at www.clearpointneuro.com, by selecting “Investors” / “News” / “IR Calendar.” ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy.